{
  "provider": "gemini",
  "exit_code": 0,
  "cli_output": {
    "response": "Analysis complete",
    "stats": {
      "tokens": {
        "prompt": 1000,
        "candidates": 500
      }
    }
  },
  "structured": {
    "analysis_summary": "Defensive strategy focusing on dividend aristocrats with recession protection.",
    "overall_sentiment": "neutral",
    "overall_confidence": 70,
    "recommendations": [
      {
        "ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "action": "BUY",
        "current_price": 162.30,
        "target_price": 175.00,
        "confidence": 80,
        "investment_thesis": "Healthcare giant with diversified revenue streams and consistent dividend growth. Defensive qualities attractive in uncertain markets.",
        "key_metrics": {
          "pe_ratio": 15.2,
          "dividend_yield": 3.1
        },
        "position_size_pct": 7.5,
        "risk_factors": [
          "Litigation risks",
          "Patent expirations"
        ],
        "catalysts": [
          "New drug approvals",
          "Dividend increase"
        ]
      }
    ]
  }
}
